Janux therapeutics to present virtually at the h.c. wainwright bioconnect conference

San diego--(business wire)--janux therapeutics, inc. (nasdaq: janx) (janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its tumor activated t cell engager (tractr) and tumor activated immunomodulator (tracir) platforms, today announced that janux management will participate in a fireside chat at the virtual h.c. wainwright bioconnect conference being held january 10 to 13. the fireside chat will be available for on-
JANX Ratings Summary
JANX Quant Ranking